With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Regional expansion in healthcare attracts sector investment
The Italian Government’s focus on strengthening its healthcare facilities, including restructuring of its primary healthcare system following COVID 19, has attracted Sysmex Corporation, to build its market share through newly established direct sales and services of its haematology, urinalysis and hemostasis products as from April 2024. Offered through its affi liate Sysmex Italia SRL (formerly Sysmex Partec Italia SRL), this expands the company’s existing portfolio of direct service provision in the fi elds of life sciences and industrial fl ow cytometry monitoring (FCM) already being provided.
Against a background of steadily growing expenditure on healthcare, with suggested forecast to exceed €180 billion in 2025, the company has been building its sales and services in Italy with distributors over the last 30 years or more, currently reporting a market share of over 50% in the fi eld of haematology.
The business’ strategic aims are to boost its haematology and urinalysis business by providing globally standardised product training, enhancing its Sysmex ICT-based customer support and the introduction of products with high added value. It will also be leveraging its customer base in the haematology fi eld to increase market share in the fi eld of hemostasis and make full use of customer feedback to capture markets in new business areas such as clinical FCM2 tests and immunochemistry.
Efforts to put in place and strengthen sales and services and support systems will enable Sysmex to further contribute to the development of healthcare, the company said.
More information:
ilmt.co/PL/JRX8 62242pr@reply-direct.com
Japanese hospital to evaluate
technology used in European trials
Leading stem cell researchers at Shonan Kamakura General Hospital (SKGH), Japan, are collaborating with regenerative cell therapy developer CellProthera to manufacture autologous endothelial progenitor cells (EPCs) for use in forthcoming clinical trials. Led by world-renowned stem cell expert Takayuki Asahara, MD, PhD, the SKGH research team will use the company’s automated manufacturing technology, along with single- use cell culture kits to produce therapies for patients with ischemic and renal diseases.
Collaboration to strengthen quantum communications networks
JOSEON, which is also the historic name for the Kingdom of Korea, is one of four Korea-Europe Quantum Science and Technology Collaboration Centres selected for funding by the National Research Council of Korea. It will be supported by £2.8 million in funding across its lifespan.
During a ceremony to kick-start the project, also attended by visiting research students at Glasgow’s Mazumdar- Shaw Advanced Research Centre, Professor Chong said: “I am delighted to be working with my good friend Professor Robert Hadfi eld, who is a renowned expert in superconducting photon detectors. I am impressed by the superb facilities in the ARC and the James Watt Nanofabrication Centre at the University of Glasgow.”
Professor Hadfi eld (right) showing Professor Yonuk Chong and visiting postgraduate researchers Dongki Cho and Beomgyu Choi at the Quantum Sensors Laboratories in the University of Glasgow ARC (Credit: University of Glasgow)
An international partnership to create next-generation superconducting photon detectors for applications such as secure quantum communication networks in optical fi bre and space, has been announced by the University of Glasgow and the Sung Kyung Kwan University (SKKU) in the Republic of Korea.
The fi ve-year ‘Joint research centre in Superconducting Electro-Optic technology for Near-infrared single photon counting’ project, (JOSEON), will be led by Professor Robert Hadfi eld, of the James Watt School of Engineering, at Glasgow and Professor Yonuk Chong, of the SKKU Advanced Institute of Nanotechnology.
Professor Hadfi eld added: “It is a great honour that our project was selected by the National Research Foundation of Korea. This will facilitate exchange of expertise on superconducting devices and accelerate scientifi c progress on emerging quantum technologies.
“I am very pleased to be hosting Dongki Cho and Beomgyu Choi as visiting postgraduate researchers and I am looking forward to visiting Professor Chong’s labs and facilities at SKKU Suwon.”
The JOSEON partnership builds on a Memorandum of Understanding on Research Co-operation between the University of Glasgow and SKKU signed in March 2022.
More information online:
ilmt.co/PL/Qmjk 62250pr@reply-direct.com
Professor Asahara, Deputy Director of Shonan Research Institute of Innovative Medicine at SKGH, was the fi rst researcher to isolate EPCs from peripheral blood. EPCs are naturally deployed in the body to repair blood fl ow after it is restricted (as in ischemic stroke).
CellProthera’s StemXpand, which has been in use in European trials to grow patients’ own cells into a therapeutic dose, will be rigorously tested to meet SKGH’s manufacturing specifi cations and adapted as needed to begin qualifi cation runs for an upcoming clinical trial. After the collaborators confi rm consistency and reproducibility both in the manufacturing process and with the previously manufactured product, Professor Asahara’s team will perform validation runs to ready the technology’s use for clinical testing.
“We are honoured to work with Professor Asahara given his ground-breaking experience in the regenerative medicine space and think he is the ideal partner to demonstrate the utility of our manufacturing technology beyond our own pipeline,” said Matthieu de Kalbermatten, CEO, CellProthera. “As a long-time advocate for the use of stem cells for the treatment of ischemic and renal diseases, I am hopeful this collaboration will pave the way for the StemXpand and StemPack to play a pivotal role in the research and development of stem cell treatments across the globe.”
“Ischemic diseases remain one of the leading causes of death in Japan, with limited treatment options,” commented Professor Asahara. “We hand-picked CellProthera for collaboration based in part on how StemXpand, a tried and trusted technology, will help us meet the needs of patients with ischemic diseases through our development of targeted stem cell therapies.”
More information online:
ilmt.co/PL/6KVe 62251pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia. Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
